Canaccord analyst John Newman maintained a Buy rating on Agios Pharmaceuticals (NASDAQ:AGIO) with a price target of $111, as the company will present …
In a research report issued Friday, Canaccord Genuity analyst John Newman reiterated a Buy rating on Jazz Pharmaceuticals (NASDAQ:JAZZ) with a $163 price target, …
In a research report released today, Canaccord analyst John Newman reiterated a Buy rating on shares of NPS Pharma (NASDAQ:NPSP) with a $42 price target, following concerns …
In a research report issued today, Canaccord analyst John Newman upgraded shares of Medivation (NASDAQ:MDVN) to Buy from Hold and doubled his price target to $132 …
In a research report released today, Canaccord analyst John Newman reiterated coverage with a Buy rating on Lannett Company (LCI), and a $55.00 price target.
In a report issued yesterday, Canaccord Genuity analyst John Newman assigned a Hold rating on shares of AcelRx Pharmaceuticals (ACRX) with a price target of $8, following ACRX’s Zalviso …
In a research note published yesterday, Canaccord Genuity analyst John Newman reaffirmed a Buy rating on Alcobra (ADHD), and a $40 price target, …
In a research note released yesterday, Canaccord Genuity analyst John Newman maintained a Hold rating on Acorda Therapeutics (ACOR) and reduced his price …
In a research note issued earlier today, Canaccord analyst John Newman reiterated coverage with a “Buy” rating on Lannett Company, Inc. (LCI), and a …
